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I. INTRODUCTION 
India’s pharmaceutical industry is important for its economic growth. The 
industry is also a global leader. The Indian pharmaceutical sector is ranked 3rd in 
terms of volume and 14th in terms of value (Gopalakrishnan and Vijay, 2017). The 
pharmaceutical industry also contributes around 4% to India’s GDP and generates 
significant employment. However, the ongoing COVID-19 pandemic has adversely 
affected almost all sectors of the Indian economy (Dev and Sengupta, 2020; Mishra, 
Rath and Dash, 2020; Rath and Akram, 2020; Prabheesh, 2020).1 
The aim of this paper is to examine the impact of the COVID-19 pandemic 
on the Indian pharmaceutical industry. We focus on the pharmaceutical industry 
because of the following reasons. First, the Indian pharmaceutical industry is 
entirely transformed in terms of its production capacity, innovation and adoption 
of technologies from mid-1990s (Kale, 2019; Kale and Little, 2007; Athreve and 
Godley, 2009). Second, the government of India provides the fiscal incentives 
for pursuing research and development and came up with specific trade related 
intellectual property rights to boost exports, which significantly improved the 
productivity of the Indian pharmaceutical industry (Sharma, 2012). Third, since 
several countries aim to develop a COVID-19 vaccine, the Ministry of Health and 
Family Welfare (MoHFW) of the Government of India has been providing various 
incentives and support to Indian pharmaceutical companies. These incentives are 
likely to have a positive impact on this sector. 
1 There are sectoral analysis for other countries as well, see He, Sun, Zhang & Li (2020) and He, Niu, 
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Figure 1.
Output and Employment Growth Rates of Pharmaceutical Industry
This figure illustrates output growth as well as employment growth rates of Indian pharmaceutical industry during 
2010 to 2019.
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Fourth, the overall performance of the Indian pharmaceutical industry, both 
in terms of output and employment, is impressive, particularly during 2010s (see 
Figure 1). Similarly, the average price of pharmaceutical stocks in India shows an 
upward trend during the COVID-19 period (see Figure 2). 
There is an emerging literature on the effects of COVID-19, such as on the 
financial markets, energy markets, and various sectors of the economy. The main 
conclusion of these studies is that the global financial risk has not only increased 
substantially due to the COVID-19 pandemic but has also negatively affected 
stock and oil prices. 
In this literature, however, there are only a few studies which examine the 
impact of COVID-19 on firm or industry level performance. Some exceptions are 
Shen et al. (2020), Gu et al. (2020), He et al. (2020), and Seungho et al. (2020). Shen et 
al. (2020) investigate the impact of the COVID-19 pandemic on firm performance 
by using financial data of Chinese companies. They find that COVID-19 negatively 
affects firm performance. Similarly, Seungho et al. (2020) examine the effect of 
COVID-19 on stock market volatility and find both negative and positive impacts 
of COVID-19. In the case of India: (a) Mishra et al. (2020) examine the impact of 
COVID-19 and find that it negatively impacts the Indian financial market; and (b) 
Rath and Akram (2020) show that the COVID-19 pandemic caused electricity spot 
price.2 
2 While we do not undertake a formal literature review, we refer interested readers to special issues 
of some journals such as Emerging Markets Finance and Trade (see Sharma & Sha, 2020; Sha & Sharma, 
2020; Phan & Narayan, 2020); Energy Research Letters (see Narayan, 2020a; Devpura & Narayan, 2020); 
Asian Economics Letters (see Devpura, 2020; Narayan, 2020a,b; Sharma, 2020; Iyke, 2020). We only 
refer to dedicated special issue papers rather than individual journal papers as on this there are 
many papers.
Figure 2.
Daily Average Stock Closing Price of Pharmaceutical Industry
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One gap in this literature is with regard to the lack of emphasis on how 
COVID-19 has impacted the pharmaceutical industry. This paper aims to fill this 
research gap. Our goal is to examine whether the COVID-19 outbreak affects 
abnormal returns and cumulative abnormal returns of the Indian pharmaceutical 
industry. 
The novelties of this study are as follows. First, studies on the impact of the 
COVID-19 pandemic on the Indian economy to-date have mostly focused at 
the macro level but our study focuses on the impact of COVID-19 at the micro 
level. We purposively pick the pharmaceutical industry because the performance 
of this industry during the pandemic is likely to be different as compared to 
other industries given that this industry is actively involved in recovery and 
mitigating efforts following the onset of the pandemic. Second, we also compare 
the effect of the COVID-19 pandemic on abnormal returns of automobile and 
realty sectors. Both automobile and realty sectors are severely affected by the 
pandemic. Therefore, we aim to find whether our results for the pharmaceutical 
sector differ from those two sectors. Third, we consider COVID-19 as an event 
and employ an event study methodology to examine the impact of COVID-19 on 
the pharmaceutical companies in India. Our study extends the work of Ramelli 
and Wagner (2020), and Yan (2020) by conducting an event study to examine the 
impact of the pandemic shock. The difference is we focus on the pharmaceutical 
stock returns of India. 
We find that the average abnormal returns of the pharmaceutical sector are 
positive and statistically significant. The average cumulative abnormal returns are 
also positive and statistically significant for the pharmaceutical industry. However, 
when we analyze individual firms, mixed evidence (sign wise) on abnormal 
returns are noticed due to COVID-19. We also use the Fama and French (1993) 
3-factor model to examine the impact of firm-specific events on returns. Finally, 
we use sectoral indices (pharma, auto and reality) to examine the robustness of 
our results. We find a mixed response (both positive and negative signs) of returns 
for pharma, auto and reality sectors, which is consistent with the results from the 
firm level analysis. 
The remaining sections of this paper are as follows. Section II presents the data 
and methodology. The empirical results are discussed in section III and section IV 
concludes. 
II. DATA AND METHODOLOGY
This study is based on secondary data by emphasizing on nine pharmaceutical 
firms, which are chosen based on market capitalization. Further, we consider 
the CNX Nifty index returns as a proxy for market returns as it has the highest 
trading volume. The closing price of the nine pharmaceuticals and the key indices 
(pharma, auto and realty sectors) are collected from the Center for Monitoring 
Indian Economy (CMIE) database for the period December 03, 2019 to May 28, 
2020. The sample is based on availability of data. We consider January 30 as an 
event day as the MoHFW officially reported the first COVID-19 positive case in 
India. Furthermore, we consider 10 days pre- and post-event days for the analysis 
(Kritzman, 1994). To analyze the Fama and French 3-factor model, we collect 
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Small-Minus-Big (SMB) and High-Minus-Low (HML) data from Agarwalla et al. 
(2013). Further, the 91-day Treasury bill rate data are collected from the Reserve 
Bank of India database for the analysis. 
The paper uses an event study approach and the Fama and French 3-factor 
model to study the impact of COVID-19 on pharmaceutical firms’ returns. Each 
methodology is described in detail as follows:
A. Event Study
We consider the COVID-19 pandemic as an event and study its impact on return 
series for the pharmaceutical companies. As the first COVID-19 case is reported on 
January 30, 2020 by the MoHFW and hence the present study considers that as the 
event day. Furthermore, ten days before and after the event day are considered as 
a window period. Similarly, December 3, 2019 to January 15, 2020 is considered a 
window estimation period. 
We calculate normal, abnormal, and cumulative abnormal returns during the 
estimation window period based on the following model:
In equation 1, Rit is the pharmaceutical stock price return, where i=1…9 at time 
period t and Rmt refers to market return, m=1 and εit means error term i=1…9. They 
are the parameters to be estimated. We then calculate abnormal returns (AR) and 
cumulative abnormal returns (CAR) using equation 2 as:
(1)
Where ERit stands for expected returns and i=1…9 at time period t.
 
B. Fama and French 3-Factor Model
Next, the Fama and French (1993) 3-factor model is used to check the impact of 
firm-specific events on return series. In this regard, to capture other commonly 
known market risks, which are shown to be relevant (see, for instance, Narayan et 
al. 2017), we employ the following model: 
(2)
In Equation 3, Rit refers to asset return over time, t where i= 1, 2…9, Rft is the 
risk free interest rate which is the 3-month Treasury bill rate, Rmt refers to the CNX 
Nifty returns over time t, SMBt is difference between small portfolios and big 
portfolios, HMLt is the difference between high value portfolio and small value 
portfolio. 
(3)
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III. EMPIRICAL RESULTS 
In this section, we analyze AR and CAR obtained for the nine pharmaceutical 
firms. Table 1 reports the AR of Alkem Laboratories, Abbott India Ltd, and 
Aurobindo companies. For Alkem Laboratories, we see a positive and statistically 
significant AR in the post-COVID day. One likely reason could be higher demand 
for pharmaceutical products during the pandemic; hence, a higher share price. On 
the other hand, the AR of Abbott India and Aurobindo show mixed results (both 
positive and negative returns) in the post-COVID period. 
Table 1.
Results of Alkem Labourites, Abbott India, and Aurobindo Companies
This table has abnormal returns (AR) and the corresponding t-statistics for Alkem Labourites, Abbott India, and 




AR t-statistics AR t-statistics AR t-statistics
E-10 -0.00 -0.51 -0.01 -1.06 -0.02 -1.65
E-9 -0.01 -1.25 -0.00 -0.27 0.01 1.40
E-8 0.00 0.42 0.01 1.30 0.00 0.52
E-7 -0.00 -0.45 0.00 0.83 0.02 1.83
E-6 -0.00 -0.22 0.00 0.33 0.01 1.10
E-5 -0.01 -1.54 -0.00 -0.29 -0.02 -1.85
E-4 0.00 0.17 -0.01 -1.05 0.01 0.89
E-3 0.00 0.03 0.01 1.22 0.03 2.36*
E-2 -0.01 -1.50 0.00 0.32 -0.00 -0.52
E-1 -0.01 -1.32 -0.00 -0.32 -0.00 -0.27
E-0 -0.00 -0.48 -0.00 -0.37 -0.04 -3.17**
E+1 0.03 3.23** 0.00 0.34 0.00 0.69
E+2 -0.01 -0.96 0.03 3.15** 0.01 0.93
E+3 -0.00 -0.76 0.01 1.14 0.00 0.63
E+4 0.00 0.10 -0.01 -0.90 0.01 0.81
E+5 -0.00 -0.02 -0.00 -0.02 -0.00 -0.17
E+6 0.03 3.12* 0.07 6.59* 0.07 5.04*
E+7 0.02 2.32* 0.05 4.42* -0.00 -0.09
E+8 0.01 1.13 -0.02 -2.19* 9.59 0.00
E+9 -0.00 -0.16 0.01 1.22 -0.01 -1.31
E+10 -0.01 -1.31 0.005 0.50 -0.03 -2.18*
The AR of Cipla, Dr. Reddy and Lupin are reported in Table 2. It is observed that 
COVID-19 has a positive impact on AR of Cipla and Dr. Reddy. However, during 
the pre-COVID period, AR of Lupin Dr. Reddy was also statistically significant. 
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Table 3 reports the return series of Sun Pharma, Torrent, and Zydus Wellness. 
The COVID-19 pandemic has impacted Sun Pharma and Torrent. However, during 
the pre-COVID period, the AR of Zydus wellness was statistically significant. This 
indicates that the firm-specific events do play a major role in AR.
Table 2.
Results of Cipla, Dr. Reddy and Lupin Companies
This table has abnormal returns (AR) and the corresponding t-statistics for Cipla, Dr. Reddy and Lupin. Finally, * and 
** denote statistical significance at the 1% and 5% levels, respectively.
EVENT 
WINDOW
CIPLA DR. REDDY LUPIN
AR t-statistics AR t-statistics AR t-statistics
E-10 -0.00 -0.90 0.00 0.64 0.00 0.68
E-9 -0.00 -0.04 0.03 3.62 0.01 2.47**
E-8 0.00 0.57 0.00 1.06 -0.03 -4.25**
E-7 -0.01 -1.17 0.00 0.04 0.01 2.31
E-6 -0.00 -0.11 0.00 0.09 0.00 0.44
E-5 -0.01 -1.82 -0.00 -1.05 -0.00 -0.50
E-4 -0.01 -1.78 -0.00 -0.41 0.00 0.04
E-3 0.01 1.81 0.05 5.87 0.02 3.58**
E-2 0.00 0.32 0.00 0.04 0.00 0.16
E-1 -0.01 -1.14 -0.01 -1.63 -0.00 -0.85
E-0 -0.01 -1.84 0.00 0.31 -0.01 -1.63
E+1 -0.00 -0.57 -0.01 -1.41 -0.00 -0.74
E+2 0.00 0.80 0.012 1.39 0.00 1.14
E+3 -0.00 -0.71 0.02 3.00** -0.00 -0.10
E+4 -0.00 -0.86 -0.03 -4.08* -0.00 -0.61
E+5 -0.02 -2.09* 0.00 0.78 -0.00 -0.27
E+6 0.00 0.93 0.00 0.27 -0.01 -1.86
E+7 0.00 0.63 -0.00 -0.59 -0.00 -0.05
E+8 0.00 0.80 0.01 1.33 0.00 0.11
E+9 -0.01 -1.41 -0.00 -0.03 -0.00 -0.94
E+10 -0.00 -0.68 0.03 4.46** 0.00 0.60
Table 3.
Results of Sun Pharma, Torrent and Zydus Wellness Companies
This table has abnormal returns (AR) and the corresponding t-statistics for Sun Pharma, Torrent and Zydus. Finally, 
* and ** denote statistical significance at the 1% and 5% levels, respectively.
EVENT 
WINDOW
SUN PHARMA TORRENT ZYDUS
AR t-statistics AR t-statistics AR t-statistics
E-10 -0.00 -0.90 0.00 0.64 0.00 0.68
E-9 -0.00 -0.04 0.03 3.62 0.01 2.47**
E-8 0.00 0.57 0.00 1.06 -0.03 -4.25**
E-7 -0.01 -1.17 0.00 0.04 0.01 2.31
E-6 -0.00 -0.11 0.00 0.09 0.00 0.44
E-5 -0.01 -1.82 -0.00 -1.05 -0.00 -0.50
E-4 -0.01 -1.78 -0.00 -0.41 0.00 0.04
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The CAR of all nine firms are reported in Table 4. We observe that COVID-19 
has a positive impact on Abott India and Torrent, and a negative impact on Sun 
Pharma. Further, majority the companies are showing a positive CAR during the 
estimation window period. However, the existence of a negative CAR contradicts 
the previous literature. Further, to get conclusive results, we use pharmaceutical 
average for our analysis. The results are reported in Table 4. We find that COVID-19 
has a positive impact on CAR of pharmaceutical firms. Therefore, we can conclude 
that the COVID-19 pandemic does affect the pharmaceutical sector positively. The 
finding of our study aligns with the observation made by Dondelli et al. (2017).
EVENT 
WINDOW
SUN PHARMA TORRENT ZYDUS
AR t-statistics AR t-statistics AR t-statistics
E-3 0.01 1.81 0.05 5.87 0.02 3.58**
E-2 0.00 0.32 0.00 0.04 0.00 0.16
E-1 -0.01 -1.14 -0.01 -1.63 -0.00 -0.85
E-0 -0.01 -1.84 0.00 0.31 -0.01 -1.63
E+1 -0.00 -0.57 -0.01 -1.41 -0.00 -0.74
E+2 0.00 0.80 0.012 1.39 0.00 1.14
E+3 -0.00 -0.71 0.02 3.00** -0.00 -0.10
E+4 -0.00 -0.86 -0.03 -4.08* -0.00 -0.61
E+5 -0.02 -2.09* 0.00 0.78 -0.00 -0.27
E+6 0.00 0.93 0.00 0.27 -0.01 -1.86
E+7 0.00 0.63 -0.00 -0.59 -0.00 -0.05
E+8 0.00 0.80 0.01 1.33 0.00 0.11
E+9 -0.01 -1.41 -0.00 -0.03 -0.00 -0.94
E+10 -0.00 -0.68 0.03 4.46** 0.00 0.60
Table 3.
Results of Sun Pharma, Torrent and Zydus Wellness Companies (Continued)
Table 4.
Cumulative Abnormal Return
This table has abnormal returns (AR) and the corresponding t-statistics for all nine firms. Finally, * and ** denote 
statistical significance at the 1% and 5% levels, respectively.
Company Name
 Pre-Event (10 days) Post-Event (10 days) Window Period     (21 days)
CAR t-statistics CAR t-statistics CAR t-statistics
Alkem Laborites -0.06 -1.72 0.04 1.28 0.00 0.16
Abbott India 0.01 0.36 0.16 5.21** 0.17 3.75**
Aurobindo 0.05 1.31 0.06 1.50 0.07 1.72
Cipla -0.04 -1.51 -0.03 -1.11 -0.09 -2.26*
Dr. Reddy 0.07 2.96** 0.04 1.83 0.12 3.38**
Lupin 0.03 1.17 -0.02 -0.78 -0.00 -0.05
Sun Pharma 0.00 0.21 -0.06 -2.15* -0.07 -1.65
Torrent 0.03 1.17 0.07 2.53** 0.11 2.62**
Zydus Wellness 0.02 1.02 -0.02 -0.88 -0.00 -0.17
Average 0.01 0.64 0.10 4.49** 0.11 3.53**
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After obtaining mixed responses of CAR by considering COVID-19 as an 
event, we attempt to examine the impact of lockdown due to COVID-19 on CAR 
in the case of pharmaceutical firms. The lockdown in India started on March 25, 
2020. The CAR results are reported in Table 5. We find that lockdown has a positive 
impact on majority the pharmaceutical firms. Further, during the estimation 
window periods, the majority of pharmaceutical firms show a positive CAR 
because of the lockdown. Finally, the lockdown also has a positive impact on the 
CAR of pharmaceutical industry. Therefore, we find that both the COVID-19 and 




India officially started lockdown on 24/03/2021. We calculate cumulative abnormal returns (CAR) and the 
corresponding t-statistics for all nine pharma firms by taking the lockdown as an event. This table has these results. 
Finally, * and ** denote statistical significance at the 1% and 5% levels, respectively.
Company Name
Pre-Event (10 days) Post-Event (10 days) Window Period(21 days)
CAR t-statistics CAR t-statistics CAR t-statistics
Alkem Laborites -0.09 -2.29** 0.01 2.91* 0.00 0.12
Abbott India 0.02 2.64* 0.14 3.04* 0.29 4.27*
Aurobindo -0.02 -0.31 0.10 0.82 0.13 1.09
Cipla 0.08 2.11** 0.31 7.53* 0.39 6.47*
Dr. Reddy -0.08 -1.92** 0.20 4.77* 0.15 2.40*
Lupin 0.02 0.58 0.20 5.39* 0.24 4.47*
Sun Pharma -0.00 -0.47 0.20 4.71* 0.23 3.61*
Torrent -0.06 -1.54 0.29 6.66* 0.11 2.62*
Zydus Wellness -0.01 -1.59 0.08 1.68 0.12 3.41*
Average 0.05 1.47 0.23 6.72* 0.16 4.83*
We also analyze whether any specific market risk factors had any role in 
influencing abnormal returns. Therefore, we apply the Fama and French 3-factor 
model, where we add SMB and HML to the model. The results are reported in 
Table 6. We find that market risk factors affect the individual return series. Further, 
firm size affects the firm return series positively and statistically significantly in 
the case of Cipla.
Bulletin of Monetary Economics and Banking,
Volume 24, 14th BMEB Call for Papers Special Issue (2021)10
A. Robustness Check 
Finally, to check the robustness, we consider the return series of pharma index. 
Then, we apply the event study on the return series. Results are reported in 
Table 7. We find the event has both positive and negative effects on returns of the 
pharma index which is consistent with the results from the firm level analysis. 
Furthermore, we compare the pharma index with the auto and reality indices to 
see the impact of the COVID-19 pandemic. We find that COVID-19 has impacted 
auto and reality indices. Further, we calculate the CAR of all three indices. The 
results are reported in Table 8, and indicate that COVID-19 has had a negative 
impact only on the reality sector. 
 Alternatively, following Narayan et al. (2017), we use buy-and-hold abnormal 
return (BHAR) method for the robustness of the results. The BHAR for a 
pharmaceutical stock i over an interval trading day between T1 and T2 is calculated 
as follows:
Table 6.
Fama and French 3-factor Model
This table reports results of the Fama and French 3-factor model, where EMR is the expected market risk, SMB is the 
size factor and HML is the value factor, respectively. The t-statistic is reported in parenthesis. Finally, * and *** denote 
statistical significance at the 1% and 10% levels, respectively.
Firm constant t-statistics EMR t-statistics SMB t-statistics HML t-statistics
Abott -0.25 -2.56 0.83* 13.70 -0.01 -0.59 0.02 0.89
Alkem -0.27 2.62 0.82* 12.45 0.015 0.64 0.00 0.09
Aurobindo 0.16 1.08 1.10* 11.84 0.065*** 1.86 -0.06 -1.58
Cipla -0.06 -0.61 0.95* 14.44 0.01 0.73 0.00 0.03
Dr. Reddy -0.11 -1.36 0.92* 17.22 0.00 0.34 0.00 0.19
Lupin -0.11 -0.92 0.92* 12.77 0.01 0.54 0.00 0.01
Sun Pharma -0.01 -0.19 0.98* 17.76 0.00 0.41 -0.00 -0.06
Torrent -0.28 -2.68 0.82* 12.64 0.02 0.86 -0.01 -0.47
Zydus -0.36 -3.57 0.77* 12.19 0.01 0.64 -0.00 -0.01
where  is the BHAR for firm i over an interval of trading days 
between T1 and T2; Rit is the actual returns for pharmaceutical company i at time t; 
and Rmt is the actual market returns at time t. The results are reported in Table 9. 
We notice that the results are consistent with those obtained from the event study 
approach.
 (4)
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Table 7.
Results of Abnormal Returns from Pharma, Auto and Reality Indices
This table has abnormal returns (AR) and the corresponding t-statistics for Pharma, Auto and Reality sectors. Finally, 




AR t-statistics AR t-statistics AR t-statistics
E-10 0.00 0.50 -0.00 -0.01 0.00 0.63
E-9 0.01 1.98** 0.00 0.46 0.00 0.05
E-8 -0.00 -0.28 0.00 0.80 0.01 1.35
E-7 0.00 0.41 -0.00 -0.61 -0.01 -0.91
E-6 0.00 0.16 -0.00 -0.11 0.00 0.33
E-5 0.00 0.26 -0.00 -0.04 0.01 1.22
E-4 -0.00 -0.37 -0.00 -0.48 -0.00 -0.31
E-3 0.02 2.36 0.01 1.58 0.00 0.42
E-2 0.00 0.45 -0.00 -0.44 0.00 0.46
E-1 -0.00 -0.42 -0.00 -0.16 -0.00 -0.21
E-0 -0.01 -1.77 0.00 0.81 0.00 0.29
E+1 -0.00 -0.87 -0.00 -0.20 0.01 1.55
E+2 -0.00 -0.02 0.01 1.51 -0.05 -4.94*
E+3 -0.00 -0.82 0.00 0.82 0.01 1.00
E+4 0.00 0.73 -0.02 -2.34** 0.00 0.22
E+5 -0.00 -0.47 -0.01 -1.10 0.01 1.22
E+6 0.01 1.19 -0.00 -0.52 -0.00 -0.47
E+7 0.01 1.79 -0.00 -0.46 -0.01 -1.38
E+8 -0.00 -0.65 -0.01 -1.81 -0.00 -0.43
E+9 0.00 0.50 -0.00 -0.61 -0.00 -0.45
E+10 -0.01 -1.21 -0.00 -0.71 -0.01 -1.50
Table 8.
Cumulative Abnormal Returns of Three Indices
This table has cumulative abnormal returns and the corresponding t-statistics of Pharma, Auto and Reality sectors. 
Finally, * denotes statistical significance at the 1% level.
Index
Pre-Event (10 days) Post-Event (10 days) Window Period (21 days)
CAR t-statistics CAR t-statistics CAR t-statistics
Pharma 0.04 1.47 0.00 0.04 0.04 0.92
Auto 0.00 0.20 -0.05 -1.16 -0.03 -0.54
Reality -0.54 -13.97* -0.05 -1.51 -0.02 -0.37
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IV. CONCLUSION
The literature on the effects of COVID-19 is evolving; however, to the best of our 
knowledge, none of the previous studies have examined the impact of COVID-19 
pandemic on the Indian pharmaceutical sector. Doing so is important because this 
sector is at the forefront of the fight against the pandemic. We investigate the effect 
of the COVID-19 pandemic on nine Indian pharmaceutical firms and the pharma 
average. By employing an event study methodology, we find that the abnormal 
and cumulative abnormal returns are positive and statistically significant for 
the pharmaceutical industry during the COVID-19 pandemic. However, mixed 
results of abnormal returns are noticed when comparing our results at individual 
firm level. We also use lockdown as a result of COVID-19 as an event and examine 
the impact of the lockdown on pharmaceutical firms. We observe similar patterns 
of the positive effect of COVID-19 on pharmaceutical firms. Finally, to check the 
robustness of results, we use both event study and BHAR methods, and find 
consistency in our results.
From a policy perspective, the Indian government should be vigilant on 
price stabilization of pharmaceutical products during the pandemic and help the 
pharmaceutical firms either by providing subsidies or through reducing corporate 
tax and tariffs during the COVID-19 pandemic. As India is a leader in the world 
pharmaceutical products market, incentives from the government can increase 
the production of COVID-19 vaccines, which can further boost exports from the 
pharmaceutical industry. 
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This table has the BHAR results and the corresponding t-statistics for Pharma, Auto and Reality sectors. Finally, *** 
denote statistical significance at the 10% level.
Index
Pre-Event (10 days) Post-Event (10 days) Window Period(21 days)
CAR t-statistics CAR t-statistics CAR t-statistics
Pharma 0.04 1.52*** -0.01 0.33 0-02 0.52
Auto 0.00 0.84 -0.04 -1.50*** -0.04 -1.00
Reality 0.04 1.04 -0.05 -1.38*** -0.01 -0.18
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